CURRICULUM VITAE

Emmanuel O. Akala, R.Ph., Ph.D.

**** ****** **** *****

Mitchellville, MD 20721

Tel: 301-***-**** or 301-***-**** Fax:301-***-****

e-mail: acf50a@r.postjobfree.com or acf50a@r.postjobfree.com

EDUCATIONAL BACKGROUND:

B.Pharm. (Honors:Pharmacy) 1980, University of Ife, Ile-Ife, Nigeria. Dissertation title: "Modes of

Action of Some Peptide Antibiotics".

Mentor: E. O. Ogunlana, Ph.D. (Professor).

M.Sc. Pharmaceutics, 1983, University of Ife, Ile-Ife, Nigeria. Thesis title: "Assessment of

Cassava Starch Binder on Granules and Tablets”

Mentor: R.N. Nasipuri, Ph.D. (Professor)

Ph.D. Pharmaceutics, 1986, The University of Manchester, England.

Thesis title: "Studies on Photopolymerized PolyHEMA Hydrogel Systems for Drug Delivery".

Mentor: J.H. Collett, Ph.D., D.Sc. (Professor).

DAAD Fellow: Institute of Biopharmaceutics and Pharmaceutical Technology, University of

Muenster, The Federal Republic of Germany, 1993.

Projects: (1) Pulsatile drug delivery system using electrical energy and remote control with the aid

of a computer. (2) Studies on the characteristics of some rectal absorption enhancers using three -

dimensional solubility parameters (application of regular solution theory to transepithelial transport

of drugs).

Mentor & Collaborator: R. Groning, Ph.D. (Professor).

Fellow, National Institutes of Health Fogarty International Center, USA and Research Associate,

Department of Pharmaceutics and Pharmaceutical Chemistry / Center for Controlled Chemical

Delivery, and Department of Bioengineering, University of Utah, USA. (1994 - 1996)

Project: “Biodegradable hydrogels with controllable kinetics of swelling for colon -specific oral

peptides/proteins delivery"

Advisor & Collaborator: Jindrich Kopecek, Ph.D., D.Sc. (Distinguished Professor, Department of

Pharmaceutics and Pharmaceutical Chemistry; Distinguished Professor of Bioengineering,

University of Utah).

National Association of Boards of Pharmacy Foreign Graduate Examination (USA)

Dec.3, 1995

Research Associate, Departments of Pharmaceutics and Pharmaceutical Chemistry and

Bioengineering, University of Utah (1996 - 1997).

Registered Pharmacist (Nigeria) 1982

Registered Pharmacist (Utah) November, 1997.

Registered Pharmacist (Maryland) March, 1998.

Registered Pharmacist (Washington, D.C.) August, 1998

Immunization Pharmacist, June 2010

PROFESSIONAL EXPERIENCES:

July 1, 2011 to Date: Professor of Pharmaceutics, Department of Pharmaceutical Sciences,

College of Pharmacy, and Graduate Professor, Graduate School of Arts & Sciences, Howard

University, Washington, D.C. Co-PI and Director: Center for Drug Research and Development,

College of Pharmacy, Howard University and Director, Laboratory for Nanomedicine, Drug

Delivery, and Pharmaceutical & Biopharmaceutical Drug Products Design and Development,

College of Pharmacy, Howard University.

October 3, 2013 to Date: Member of the Advisory Group of the Center for Pharmaceutical

Advancement and Training of the United States Pharmacopeia (Appointed by Dr. Roger L.

Williams (Chair, Council of Experts, United States Pharmacopeia)).

April 2013: Emmanuel O. Akala Awarded Howard University Pharmacy Alumni

Association 2013 “Distinguished Faculty of the Year”.

October 1998 to Date: CVS/Caremark Floater Pharmacist Part-Time (Stores in Washington

and Maryland). Pharmacy Intern and Pharmacist: Smith Pharmacy, Utah: January 1996 to

December 1997.

July 1, 2003 - to July 1, 2011: Associate Professor Department of Pharmaceutical Sciences,

School of Pharmacy, College of Pharmacy, Nursing and Allied Health Sciences, and Graduate

Associate Professor, Graduate School of Arts & Sciences, Howard University, Washington, D.C.

Co-PI and Director: Center for Drug Research and Development, School of Pharmacy, Howard

University.

January 1, 1998 – June 30, 2003: Assistant Professor Department of Pharmaceutical

Sciences, School of Pharmacy, College of Pharmacy, Nursing and Allied Health Sciences, and

Graduate Assistant Professor, Graduate School of Arts & Sciences, Howard University,

Washington, D.C.

Responsibilities include instruction of Pharm. D. professional students and Ph.D. graduate

students, development of research program and seeking research grants to support the research,

public service, and publication in refereed journals. Other responsibilities inclu de participation in

the College, University, National and International Committees.

October 1, 1994 - November 30, 1997: Fellow, National Institutes of Health Fogarty International

Center, Bethesda, Maryland and Research Associate, Department of Pharmaceutics and

Pharmaceutical Chemistry/Center for Controlled Chemical Delivery, and Department of

Bioengineering, University of Utah, USA. Project advisor: Professor Jindrich Kopecek.

2

Project: “Biodegradable hydrogels with controllable kinetics of swelling for colon-specific oral

peptides/proteins delivery"

September 1, 1993 - November 30, 1993: DAAD Fellow, Institute of Biopharmaceutics and

Pharmaceutical Technology, University of Muenster, Germany. Project advisor: Professor R.

Groning. Projects: (1) Pulsatile drug delivery system using electrical energy and remote control

with the aid of a computer. (2) Studies on the characteristics of some rectal absorption enhancers

using three-dimensional solubility parameters (application of regular solution theory to

transepithelial transport of drugs).

1986-1994: Lecturer one and then Senior lecturer in Pharmaceutics, Obafemi Awolowo University,

Ile-Ife, Nigeria. Teaching at undergraduate (B.Pharm.) and postgraduate (M.Sc. and Ph.D.) levels.

Research activities: Formulation of amodiaquine and chloroquine suppositories; evaluation of corn

chaff as tabletting excipients; applications of iontophoresis technique in drug therapy; integrated

computer optimization technique for use in the formulation and development of pharmaceutical

dosage forms; application of regular solution theory to transepithelial transport of drugs.

1983-1986: Commonwealth Scholar, University of Manchester, England.

Project: Studies on Photopolymerized PolyHEMA Hydrogels for Drug Delivery.

1980-1983: Graduate Assistant and then Assistant Lecturer in Pharmaceutics, Department of

Pharmaceutics, Obafemi Awolowo University, Ile-Ife, Nigeria. Research activities: Evaluation of the

influence of cassava starch mucilage binder on granules and tablet properties.

Teaching responsibilities: Dispensing laboratories (first, second and third year professional

students).

1980-1981: Internship Program at the Teaching Hospital, University of Ife, Leading to Registration

as a Pharmacist in 1982.

1981-1982: National Youth Service Corps, St. Joseph's Hospital, Adazi, Nigeria.

HONORS AND AWARDS

Commonwealth Scholar, University of Manchester, England, 1983- 1986.

The Third World Academy of Sciences Research Grant No BC 89-25 for a project entitled

"Integrated Computer Optimization System for Use in the Formulation and Development of

Pharmaceutical Dosage Forms".

May and Baker Traveling Fellowship, 1990.

Pfizer Traveling Fellowship - Awarded in 1990 but Utilized in 1991

National Secretary of the Nigerian Association of Academic Pharmacists (1987-1990).

Chairman, Pharmaceutical Society of Nigeria, Osun State Branch (1991-1992)

DAAD Fellowship at the Institute of Biopharmaceutics and Pharmaceutical Technology, University

of Muenster, The Federal Republic of Germany, 1993.

External Examiner to the Department of Pharmaceutics and Industrial Pharmacy, University of

Ibadan, Nigeria (1992-1994).

Member of Senate, Obafemi Awolowo University, Ile-Ife, Nigeria (1992-1994).

Fellow, National Institutes of Health Fogarty International Center, USA (1994-1996).

3

Rho Chi Honor Society (2000)

Traveling Award to Attend Writing Winning Grant by the Federations of American Societies For

Experimental Biology, June 2001

Distinguished Faculty Author, President and Provost, Howard University 1998 -2000; 200-2001;

2001-2002; 2002-2003; 2004-2005; 2005-2006, 2006-2007, 2007-2008, 2008-2009, 2009-2010:

Recognition and Award by Howard University under Presidential Merit Superior Performance

Awards: 2000-2001, 2002, 2003, 2004, 2006; 2007, 2008, 2009

Howard University Pharmacy Alumni Association Distinguished Faculty (2009)

Eligible for new continuous submission throughout my tenure as NIH Grant Reviewer (July 1

2010). On the basis of my substantial service to peer review at the National Institutes of Health, I

have the opportunity to submit certain grant applications at any time.

NIH GRANT PROPOSAL STUDY SECTIONS AND GRANT REVIEWER TO OTHER AGENCIES

(a) Consultant to National Institutes of Health, Center for Scientific Review: Special Emphasis

Panel (ZRG1 SSS-O 12 B, Small Business Cardiovascular and Pharmacology). SRA: Dr. C.

Ganguly (March 6-7, 2003).

(b) Consultant to National Institutes of Health, Center for Scientific Review: Special Emphasis

Panel for Small Business Innovation Research (SBIR) and Technological Transfer (STTR) Grants

(SBIR/STTR ZRG1-HP, Hematopoiesis Study Section). SRA: Dr. Robert Su (June 2003)

(c) Consultant to National Institutes of Health, Center for Scientific Review: Biomedical Research

Review Subcommittee 2004/01 Council AA-1 (National Institute on Alcohol Abuse and Alcoholism

Initial Review Group (10/20/2003)). SRA: Sathaisiva Kandasamy, Ph.D.

(d) Consultant to National Institutes of Health, Center for Scientific Review: Cardiovascular

Sciences Special Emphasis Panel (ZRG1 SSS-O 11 B) Small Business Cardiovascular and

Pharmacology). SRA: Dr. Robert Su (November 17, 2003).

(e) NIH/NIDA RFP N43DA-4-7741 (Nanoscience-Based Design of Therapies for Substance Abuse

Treatment), January 28, 2004. Dr. Richard Harrison, Chief, Contracts Review Branch, Office of

Extramural Affairs, NIDA.

(f) Cardiovascular Science Small Business Activity (Special Emphasis Scientific Review Group:

ZRG1 CVS-H 10 B, ZRG1 CVS SBIR, March 18-19, 2004). Delia Tang, MD (Scientific Review

Administrator)

(g) N44DA-5-7741 (Topic 064) (Oral Buprenorphine Nanoparticle Formulation – Phase II SBIR –

Topic 064 Contract Proposal): HHS Procurement N44DA-5-7741 (Topic 064). May 11, 2005). Dr.

Eric Zatman (Contract Review Administrator, National Institute on Drug Abuse)

(h) Hematology Small Business (SBIR/STTR) Special Emphasis Panel Scientific Review Group:

ZRG1 Heme-D 10 B, July 15, 2005. Delia Tang, MD (Scientific Review Administrator)

(i) Reviewer to Fund for Academic Excellence Grant Program, Provost Office, Howard University.

Ten proposals were reviewed in 2005 for the Eleventh Cycle (Fall 2004-Spring 2005)

(j) Xenobiotic Disposition and Action (XNDA) Study Section: Digestive Sciences Integrated Review

Group (June 7-8, 2006). Patricia Greenwel, Ph.D. (Scientific Review Administrator)

(k) Technology Development Special Emphasis Panel (ZRG1 F14A 20L. June 29-30, 2006 .

(l) The Pharmaceutical & Chemical Resources for AIDS Drug Development Contract Review

(Microbiology Clinical Review Branch Scientific Review Program DEA, NIAID, NIH, DHHS (NIH

(ZRG)/NIAID/DEA October 2 and 3, 2006). Darren D. Sledjeski, Ph.D. (Scientific Review

Administrator).

4

(m) 2009/05 ZGM1 MBRS-X (CH) MBRS SCORE Applications

(n) New Jersey Department of Health & Senior Services Cancer Research Funding Initiative, New

Jersey Cancer Development Awards (NJDRDA), January 2009

(o) RFA OD-09-003 Challenge Grants Panel 4 (2009/10 ZRG1 BST-M (58) R (June 2009)

(p) NIH Center for Cancer Nanotechnology Excellence (CCNEs) (U54) Special Emphasis Review

Panel ZCA1 GRB-S M1 R (February 24 to 26, 2010) (Michael B. Small, Ph.D., Scientific Review

Officer).

(q) 2010 Prostate Cancer Research Program - Prostate Cancer Training Award (Scientist

Reviewer: Department of Defense Congressionally Directed Medical Research Programs) July 28 -

30, 2010 (Barbara M. Mueller, PhD, Scientific Review Officer).

(r) SBIR Topic 301 (N43 & N44): Nanotechnology Sensing Platforms for Improved

Diagnosis of Cancer, March 2, 2011 (Savvas C. Makrides, Ph.D., Scientific Review

Officer).

(s) 2011 Prostate Cancer Research Program - Prostate Cancer Training Award

(Scientist Reviewer: Department of Defense Congressionally Directed Medical

Research

Programs) August 1-3, 2011 (Victoria Kane, Ph.D. Scientific

Review Officer).

(t) Department of Defense 2012 Prostate Cancer Research Program (Pre-application-Clinical and

Experimental Therapeutics-2) MAY 7th, 2012, Barbara J. Silver, Ph.D. Scientific Review Officer.

Global Health Sector, SRA International, Inc.

(u) Department of Defense FY 2012 Prostate Cancer Research Program Training Awards: PTRA,

PTA and STPA, August 28-30, 2012. Moira Hitchens, Scientific Review Officer, SRA International,

Inc. (Health Group)

(v) NIH/NCI April 12th SBIR Contract Review (SBIR Topic 300 Review) .Jeffrey E.

DeClue, Ph.D. Scientific Review Officer NIH/NCI/DEA/SRLB

(w) NIH/NCI PAR-10-286: Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology

(SBIR [U43/U44]) July 11 to July 12, 2012. Savvas C. Makrides, Ph.D. Scientific Review Officer

(Special Review and Logistics Branch)

REVIEWER OF SCIENTIFIC JOURNALS

(a) Reviewer to the International Journal of Pharmaceutical Compounding, Edmond, Oklahoma, “In

Vitro studies on the release of morphine sulfate from compounded extended-release morphine

sulfate capsules” Lloyd V. Allen, Jr., Ph.D., R.Ph. (Editor – in- Chief).

(b) Reviewer to AAPS Pharm. Sci. (an electronic journal), “Determination of polyvinyl alcohol in a

poly(DLlactide-co-glycolide) matrix by size exclusion chromatography” Robert, Langer, D. Sc.

Germeshausen Professor of Chemical and Biomedical Engineering, School of Engineering, MIT

(Editor).

(c) Reviewer to Biomaterials, “Controlled release of cyclosporine from VP-HEMA copolymer

systems of adjustable resorption monitored by MEKC” Nicholas, A. Peppas, D.Sc. Showalter

Distinguished Professor of Chemical Engineering, School of Chemical Engineering,

Purdue University (Editor, USA).

(d) Reviewer to Journal of Biomedical Material Research, Ms # E-127 (“Self-curing acrylic

formulations containing PMMA/PCL composites: properties and antibiotic release behavior”).

James M. Anderson, M.D., Ph.D. University Hospitals of Cleveland, The Institute of Pathology of

Case Western Reserve University, Cleveland (Editor in Chief).

5

(d) Reviewer to International Journal of Pharmaceutics, “Colon-specific drug delivery: new

approaches and in vitro/in vivo evaluation”. Howard Rytting, Ph.D. Department of Pharmaceutical

Chemistry, University of Kansas, Lawrence, KS (Editor, USA).

(e) Reviewer to Biomaterials “eBioM-1103: Synthesis and biological properties of antitumor-active

conjugates of ADR with dextran”. Professor David Williams, University of Liverpool, United

Kingdom (Editor-in-Chief of Biomaterials).

(f) Reviewer to International Journal of Pharmaceutics, “Tumor Targeted Delivery of Tamoxifen

(KU-1851)”.J. H. Rytting, Ph.D. Department of Pharmaceutical Chemistry, University of Kansas,

Lawrence, KS (Editor, USA).

(g) Reviewer to International Journal of Pharmaceutics, “In vitro and in vivo release of naltrexone

from biodegradable depot systems (KU-1903)”. J. H. Rytting, Ph.D. Department of Pharmaceutical

Chemistry, University of Kansas, Lawrence, KS (Editor, USA).

(h) Reviewer to International Journal of Pharmaceutics, “Fluid Bed Drying of Guarana (Paullina

Cupana HBK) Extract: Response Surface Analysis on Process Variables)”. J. H. Rytting, Ph.D.

Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS (Editor, USA).

(i) Reviewer to AAPS Pharm. Sci. (an electronic journal). A pdgf-BB photocrosslinkable poly(vinyl

alcohol) hydrogels release vehicle for wound healing applications ”, Wolfang Sadeee, Ph.D. (Editor

in-Chief). 2003

(j) Reviewer to International Journal of Pharmaceutics, “Bioavailability Assessment of Salbutamol

Sulfate Suppositories in Human Volunteers”. J. H. Rytting, Ph.D. Department of Pharmaceutical

Chemistry, University of Kansas, Lawrence, KS (Editor, USA).

(k) Reviewer to the International Journal of Pharmaceutical Compounding: “Chemical Stability of

Phenylephrine Hydrochloride after Reconstitution in 0.9 % Sodium Chloride Injection for Infusion”,

Lloyd V. Allen, Jr., Ph.D., R.Ph. (Editor – in- Chief).

(l) Reviewer to Biomacromolecules: “Water-soluble and Nonionic Polyphosphoester: Synthesis,

Degradation, Biocompatibility and Enhancement of Gene Expression in Mouse” David L. Kaplan

(Editor), Biotechnology Center, Department of Chemical Engineering, Tufts University, MA, USA.

(m) Reviewer to the Journal of Drug Targeting. Polyacetal-diethylstilboestrol: a polymeric drug

designed for pH-triggered activation. Ijeoma F. Uchegbu (Editor, Targeting Special Polymer Edition

JDT/04, Department of Pharmaceutical Sciences, University of Strathclyde Glasgow).

(n) Reviewer to Biomacromolecules Journal. Ternary Complexes Comprising

Polyphosphoramidate Gene Carriers. Prof. Ann-Christine Albertsson (Editor). Department of Fibre

And Polymer Technology Teknikringen 58 Royal Institute of Technology (KTH) S-100 44

Stockholm, Sweden.

(o) Reviewer to Biomacromolecules Journal. PAMAM Dendrimers with A Trimesyl Core as

Gene Carriers. Prof. Ann-Christine Albertsson (Editor). Department of Fibre and Polymer

Technology, Teknikringen 58 Royal Institute of Technology (KTH) S-100 44 Stockholm, Sweden

(p) Reviewer to the Journal of Bioactive and Biocompatible Polymer. Liver-targeting Dendritic

MRI Contrast Agents Containing Pyridoxamine. Professor Raphael M. Ottenbrite, Department of

Chemistry, Virginia Commonwealth University, Richmond, VA 23284-2006 USA

(q) Reviewer to International Journal of Pharmaceutics. Pharmacokinetics and

biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. J. H.

Rytting, Ph.D. Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS

(Editor, USA)

(r) Reviewed a chapter (Paclitaxel delivery from novel polyphosphoesters: from concept to clinica l

trials) to be published in the American Chemical Society (ACS) Symposium Series Book

6

"Polymeric Drug Delivery: Science & Application”. Sonke Svenson, Ph.D.Dendritic

NanoTechnologies, Inc.2625 Denison Drive Mt. Pleasant, MI 48858

(s) Reviewer to International Journal of Pharmaceutics, “Evaluation of Nanoparticles Loaded with

Benzopsoralen A in Rat Peritoneal Exudatew Cells”. Howard Rytting, Ph.D. Department of

Pharmaceutical Chemistry, University of Kansas, Lawrence, KS (Editor, USA).

(t) Reviewer to Medical Principles and Practice, The International Journal of the Kuwait Health

Sciences Center, “Manuscript # 1340/5/2005: Determination of Simvastatin in Human Plasam by

HPLC-UV”. Editor: Azu Owunwamnne, Faculty of Medicine, Kuwait University.

(u) Reviewer to Biomacromolecules Journal. Synthesis and Crosslinking Characteristics of

Oligomeric Unsaturated Phosphosester Used as a Potential Injectable Bone Repair Material. Prof.

Ann Christine Albertsson (Editor). Department of Fibre and Polymer Technology Teknikringen 58

Royal Institute of Technology (KTH) S-100 44 Stockholm, Sweden.

(v) Reviewer to Journal of Controlled Release: Ms. Ref. No.: JCR-D-05-00135 Title: In vitro

Release of the mTOR Inhibitor Rapamycin from Poly(ethylene glycol)-b-Poly(<epsilon>

caprolactone) Micelles. Professor Kinam Park Editor-in-Chief, School of Pharmacy, University of

Wisconsin.

(w) Journal: Biomacromolecules Manuscript ID : bm-2010-00801k

Title : "Bioactive Polymeric Systems with Platelet Anti-Aggregating Activity for The Coating of

Vascular Devices" Author(s): Rodríguez, Gema; Fernández-Gutiérrez, María del Mar; Parra, Juan;

López-Bravo, Antonio; García-Honduvilla, Natalio; Buján, María Julia; Molina, María; Duocastella,

Luis; San Roman, Julio Dr. Simona Percec, Associate Editor Christi Battiato, Editorial Assistant

Biomacromolecules. August 2010 Phone: 302-***-****; Fax: 202-***-****; Email: percec-

acf50a@r.postjobfree.com

(x) American Institute of Chemical Engineers (AIChE) Journal "Equilibrium and Kinetics of

Vancomycin Adsorption on Polymeric Adsorbent" by Pavko, Aleksander; Likozar, Blaž; Seni ca,

David. Professor Nicholas A. Peppas, Associate Editor September 2010

(Y) Molecular Pharmaceutics: Cholesterol-dependent macropinocytosis and endosomal escape

control the transfection efficiency of lipoplexes in CHO Living Cells. Nov, 2011 Gordon L. Amidon,

Ph.D,. (Editor in Chief)

(Z) Molecular Pharmaceutics: Folic acid-Functionalized Nanoparticles for Enhanced Oral, Oct. 21,

2011 Gordon L. Amidon, Ph.D,. (Editor in Chief)

(A2) Nanomedicine: Nanotechnology, Biology and Medicine:: Novel self-nanoemulsifying drug

delivery systems (SNEDDS) for oral delivery of cinnarizine: design, optimization and in -vitro

assessment. January 2012 Editor-in-Chief: Lajos P. Balogh, PhD

Drug Delivery

** “2013 Top Reviewer” of the Journal of Pharmaceutical Sciences

(JPharmSci).

PROFESSIONAL AFFILIATIONS

1980 - Present: Member of the Pharmaceutical Society of Nigeria

1983 – Present: Member of the Nigerian Association of Academic Pharmacists and Quality Control

Society of Nigeria

1983- 1994: Member of Commonwealth Pharmaceutical Association

1983- 1994: Member of the Royal Society of Health

7

1994-Present: Member of Controlled Release Society

1995-Present: Member of the American Association of Pharmaceutical Scientists

1998-Present: Member of American Chemical Society

1998-Present: Member of American Association of Colleges of Pharmacy

1998-Present: Member of Research Society on Alcoholism

1998-Present: Member and Investigator at Howard University Alcohol Collaborative Research

Center

1998-2007: Member and Publicity Secretary, American Association of Nigerian Pharmacists,

Washington Metropolitan Area

2000-Present: Member and Principal Investigator, Howard University Keck Center for the Design

of Nanoscale Materials for Molecular Recognition

2002-Present: Pharmacist on Call: Bioterrorism Preparedness and Response Plan (Government of

the District of Columbia: The District of Columbia Department of Health and the

Board of Pharmacy).

2002-Present: Member Sigma Xi, The National Research Society (USA)

2002-Present: Member of Rho Chi Society: Pharmacy Academic Honor Society (Beta Sigma

Chapter, Howard University) and Chapter Faculty Advisor.

2003-Present: Member of the Education Committee of the Controlled Release Society

2008-Present: Collaboration (Surface and structural analysis of nanoparticles) with Dr. John A.

Small, the Division Chief of the Surface and Microanalysis Science Division at the

National Institute for Standards and Technology (NIST). My Ph.D. student (Simeon

Adesina) has been granted Visiting Scientist Status at NIST

2009 – Present: Collaboration (Cell culture studies, in vivo distribution studies and biomarker

based targeting of nanoparticles for cancer treatment and imaging) with Dr. Jacek

Capalla, Head, Molecular Targeting Section Radiation Oncology Branch, NCI/NIH

2009 – Present: Member, Nigerian Association of Pharmacists and Pharmaceutical Scientists in

the Americas, Inc. (NAPPSA) & Member of the Organizing Committee for the 2009 Annual

Scientific Conference and Exposition, September 17-20, 2009: Conference Theme: Drug

Development and Pharmaceutical Care in the 21st Century

2012 - Present: International Society of Pharmaceutical Engineering

2012 - Present: Parenteral Drug Assicaition (PDA)

2013 – Present: Member of the Advisory Group of the Center for Pharmaceutical Advancement

and Training of the United States Pharmacopeia

LICENSURE

Registered Pharmacist in Nigeria (1980-Present)

Registered Pharmacist in Utah (1997-Present)

Registered Pharmacist in Maryland (1998-Present)

Registered Pharmacist in Washington, DC (1998 – Present)

RESEARCH GRANTS FUNDED BEFORE JOINING HOWARD UNIVERSITY:

(A) Obafemi Awolowo University, Nigeria

A.1 Suppository Formulation of Antimalarial Drugs: Amodiaquine and Chloroquine (Obafemi

Awolowo Univeristy, Ile-Ife, Nigeria, 1987-1989: N25, 000).

8

A.2 Applications of Iontophoresis Technique in Drug Therapy (Obafemi Awolowo Univeristy, Ile-Ife,

Nigeria, 1988-1992: N20, 000).

(B) International (Outside Nigeria)

B.1 The Third World Academy of Sciences (Italy) Exploratory Research Grant No BC 89 -25 for a

Project Entitled "Integrated Computer Optimization System for Use in the Formulation and

Development of Pharmaceutical Dosage Forms, 1990 – 1992): $5,000.

B.2 DAAD Fellowship Grant by the Government of the Federal Republic of Germany: 11, 000

Germany Marks (Approximately $11,458) for Three Months, Excluding the Cost of Air Ticket.

Utilized at The Institute of Biopharmaceutics and Pharmaceutical Technology, University of

Munster.

B.3 National Institutes of Health (Fogarty International Center) Fellowship Grant, USA (1

F05TW005182-01). Utilized at the University of Utah. $65,000 for Two Years (Excluding $3,000 for

Air Flight).

RESEARCH GRANTS FUNDED AFTER JOINING HOWARD UNIVERSITY

(1) Howard University Fund for Academic Excellence: Workshop on the Applications of Polymeric

Biomaterials in Drug Delivery, Drug Targeting and Gene Delivery. Status: Funded. $2,500,

October 30, 1998. (Principal Investigator).

(2) Howard University Fund for Academic Excellence: Stimulation of Pharm.D. Degree Students’

Interest in Laboratory Research Oriented Higher Degree (Ph.D.) 1999 (Co-Principal Investigator):

PI is Dr. K.R. Scott. Funded $5,000.

(3) Howard University Fund for Academic Excellence: Reinforcing Concepts by Studying Experts:

An Integrated Approach to the Teaching of Pharmaceutics. Status: Funded. $2,500. March 12,

1999. (Principal Investigator).

(4) Howard University New Faculty Research Program: Hydrogel Drug Delivery Systems for

Peptides and Proteins”. Status: Funded. April, 1999. $47, 335 over one year. (Principal

Investigator).

(5) NIH (IU24AAA11898-03): NIH Grant Through Howard University Collaborative Alcohol

Research Center: “Polymeric Controlled Delivery System for Naltrexone for the Treatment of

Alcoholism”. Status:Funded. October, 1999. Requested $99,725 over two years ($38,151.00 for

the first year due to budget cut) (Principal Investigator).

(6) Howard University Fund for Academic Excellence: Computer-Based Pharmacokinetics

Workshop for Pharmacists and Doctors: Status: Funded. $5,000. May 15, 2000 (Principal

Investigator).

(7) InnaPhase Corporation, Philadelphia, PA: Computer-Based Pharmacokinetics Workshop for

Pharmacists and Doctors: Status: Funded. September 20, 2000 (Principal Investigator) ($4,700)

(8) 2000-2001 Merck Research Scholar Award to a Pharm.D. Student, Oluchi Uloaku Njoku

(Sponsored by My Laboratory): $5,500 for One Year (Polymeric Oral Drug Delivery System for

Proteins and Peptides)

(9) NIH (IU24AAA11898-03): Howard University Collaborative Alcohol Research Center:

“Polymeric Controlled Delivery System for Naltrexone for the Treatment of Alcoholism”. Status:

Funded. October, 1999. Requested $99,725 over two years ($43,000.00 for the second year

9

beginning in October 2000) (Principal Investigator).

(10) Investigator in the one million dollars ($1,000,000) research grant of Dean Pedro J. Lecca,

Ph.D. (RR-99-023 Extramural Research Facilities Construction and Renovation of Third Floor in

Chauncey Cooper Hall (Pharmacy Building) by writing sections of the proposal, and by submitting

abstracts of my projects, a list of funded projects, my C.V., and discussion with the NIH officials

during visitation to Howard University on this project.

(11) W. M. Keck Foundation: Keck Center for the Design of Nanoscale Materials for Molecular

Recognition January 2002- December 2003: $750,000; it was matched with $250,000 by the

President of Howard University: H. Patrick Swygert, J.D. (My project is “Nano- sized targetable

and biorecognizable dendritic biomaterials”).

(12) Eli Lilly Grant: The Synthesis of Analogs of NSC D698576 and NSC D698577 and

Development of Targetable Delivery Systems for Ovarian Cancer. June 2001. $12,500 for one

year (Co-Principal Investigator). PI is Dr. K R. Scott.

(13) Howard University Fund for Academic Excellence (Travel Fellowship): Particles 2002.

Symposium and Workshop on Medical/Biochemical, Pharmaceutical and Drug Delivery

Applications of Particle Technology, Orlando Florida, January 2002. $3,500 (Principal Investigator)

(14) National Institutes of Health: Polymeric delivery system for naltrexone. NIH Grant # 1 R21

AA13407 01 PI: AKALA, EMMANUEL O. January 2002-2006 $453, 000.

(15 ) Howard University Award (Fund for Academic Excellence: Travel Fellowship) 30th Annual

Meeting & Exposition of the Controlled Release Society, Glasgow, Scotland (July 2003) 3,000

(Principal Investigator)

(16) NIH/NCRR 1 C06 RR 020608-01 renovation of ground and first floors of Chauncey I. Cooper

Hall to house the Center for Drug Research and Development (CDRD). Principal Investigator: Dr.

Beatrice Adderley-Kelly/Dr. Pedro J. Lecca (the Dean of the College of Pharmacy, Nursing and

Allied Health Sciences). Dr. Emmanuel O. Akala is the Co-Principal Investigator and the Program

Director for the Center (I wrote the grant proposal). ($3,519,397.00: September 2004- June 30,

2009)

(17) Fund for Academic Excellence Grants Program, Cycle 11, Travel Grant Proposal ((TRAV

(CYT1106/03): Visit to the Center for Pharmaceutical Science & Technology (The Chao Center in

Purdue Research Park, Purdue University, West Lafayette, Indiana) in connection wit CDRD

development and participation in a workshop on Statistical Experimental Design July 1, 2005 to

June 30, 2006 ($3,871)

(18) Fund For Academic Excellence Grants Program, Cycle 11,Entrepreneurial Grant Proposal)

(ENTCYE 1106/01): “Center for Drug Research

Contact this candidate